Clinical Experience with Trastuzumab (Herceptin)

No abstract is available for this paper.

• Publication year

  2003

• Venue

  The Breast Journal

• Publication date

  2003-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1046/j.1524-4741.2003.09602.xPMID 14616939
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Carboplatin activity in untreated metastatic breast cancer patients — results of a phase II study

  2004cited by this paper
• Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.

  2003cited by this paper
• Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.

  2002cited by this paper
• The n e w e n g l a n d j o u r n a l of m e d i c i n e

  2001cited by this paper
• Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

  2001influential reference
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report.

  2001cited by this paper
• Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.

  2001cited by this paper
• Trastuzumab and chemotherapeutics: drug interactions and synergies.

  2000cited by this paper
• Results and long term follow‐up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin‐containing chemotherapy

  1999cited by this paper
• Monotherapy of metastatic breast cancer: a review of newer agents.

  1999cited by this paper
• Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

  1999cited by this paper
• Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

  1999cited by this paper
• Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

  1998cited by this paper
• Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

  1996influential reference
• Humanization of an anti-p185HER2 antibody for human cancer therapy.

  1992cited by this paper
• Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy.

  1989cited by this paper
• Cisplatin as first-line therapy for metastatic breast cancer.

  1988cited by this paper
• The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast.

  1988cited by this paper

• Development and validation of online SPE purification coupled to HILIC-fluorescence-MS analysis for the characterization of N-glycans.

  2023cites this paper
• Overexpression of human epidermal growth factor receptor 2 in canine primary lung cancer

  2020cites this paper
• Detection of human epidermal growth factor receptor 2 overexpression in canine anal sac gland carcinoma

  2019cites this paper
• Evaluation of immunohistochemical staining with PMab-38, an anti-dog podoplanin monoclonal antibody, in various canine tumor tissues

  2019cites this paper
• Peptide Delivery Systems for Cancer Vaccines

  2018cites this paper
• Emerging Themes in Drug Resistance

  2017cites this paper
• The current status and prospects of antibody engineering for therapeutic use: focus on glycoengineering technology.

  2015cites this paper
• Delay to Formalin Fixation Effect on HER2 Test in Breast Cancer by Dual-Color Silver-enhanced In Situ Hybridization (Dual-ISH)

  2014cites this paper
• Monoclonal Antobodies: Application in Radiopharmacy

  2014cites this paper
• Image Cytometric HER2 in Gastric Carcinoma: Is a New Algorithm Needed?

  2013cites this paper
• Production of recombinant immunotherapeutics for anticancer treatment

  2013cites this paper
• Omics Approaches and Applications in Clinical Trials

  2013cites this paper
• Expression of NRG1 and its receptors in human bladder cancer

  2011influential citation
• An analysis of HER-2/neu gene status in invasive ductal carcinomas using immunohistochemistry and fluorescence in situ hybridization

  2011cites this paper
• A statistician's perspective on biomarkers in drug development

  2011cites this paper
• HER2 Testing: How to Reach a High Concordance Rate Between Immunohistochemistry and Fluorescence In Situ Hybridization

  2011cites this paper
• Human epidermal growth factor receptor 2 protein expression between primary breast cancer and paired asynchronous local-regional recurrences.

  2011cites this paper
• Retrospective analysis of cetuximab monotherapy for patients with irinotecan-intolerant metastatic colorectal cancer

  2011cites this paper
• Quantifying factors for the success of stratified medicine

  2011cites this paper
• Investigations into the expression of sirtuins in breast cancer: in vivo and in vitro studies

  2010cites this paper
• Cancer of breast metastático study of series of cases. National institute Oncology and Radiobiología 2000-2003

  2010cites this paper
• Cáncer de mama metastático estudio de serie de casos: Instituto Nacional Oncología y Radiobiología 2000-2003

  2010cites this paper
• Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood

  2009cites this paper
• In vivo monitoring of intranuclear p27(kip1) protein expression in breast cancer cells during trastuzumab (Herceptin) therapy.

  2009cites this paper
• Production of therapeutic antibodies with controlled fucosylation

  2009cites this paper
• Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial

  2009cites this paper
• Delay to formalin fixation effect on breast biomarkers

  2009cites this paper
• Activated Stat3 in Melanoma

  2008cites this paper
• Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC

  2008cites this paper
• Quantitative PCR and HER2 testing in breast cancer: a technical and cost-effectiveness analysis.

  2008cites this paper
• Activated stat-3 in melanoma.

  2008cites this paper
• Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma.

  2008cites this paper
• HEMATOLOGIC CONDITIONS IN THE ICU

  2008cites this paper
• Evolving strategies for global gene expression analysis of cancer

  2008cites this paper
• Results from an observational trial with oral vinorelbine and trastuzumab in advanced breast cancer

  2007cites this paper
• Principles of Chemotherapy and Pharmacology

  2007cites this paper
• Specificity, selection and significance of gene amplifications in cancer.

  2007cites this paper
• Non-fucosylated therapeutic antibodies: the next generation of therapeutic antibodies

  2007cites this paper
• Targeting metastatic and advanced breast cancer.

  2007cites this paper
• High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G.

  2006cites this paper
• Pulmonary toxicity from novel antineoplastic agents.

  2006cites this paper
• Tests pharmacogénétiques : leur place en pratique médicale courante et dans le développement des médicaments

  2006cites this paper
• Nonfucosylated Therapeutic IgG1 Antibody Can Evade the Inhibitory Effect of Serum Immunoglobulin G on Antibody-Dependent Cellular Cytotoxicity through its High Binding to FcγRIIIa

  2006cites this paper
• Oral vinorelbine alone or in combination with trastuzumab in advanced breast cancer: results from a pilot trial

  2006cites this paper
• Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies

  2006cites this paper
• Identification of potentially useful combinations of epidermal growth factor receptor tyrosine kinase antagonists with conventional cytotoxic agents using median effect analysis

  2006cites this paper
• Development of antibody‐based therapeutics for oncology indications

  2006cites this paper
• Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 140 Antibody Mediated Radionuclide Targeting of HER-2 for Cancer Diagnostics and Therapy Preclinical Studies

  2006cites this paper
• Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer.

  2006cites this paper
• Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: An observational study

  2006cites this paper
• Manifestation, mechanisms and mysteries of gene amplifications.

  2006cites this paper
• Gene expression profiling in the discovery, optimization and development of novel drugs: one universal screening platform.

  2006cites this paper
• Histopathologic Characteristics Predicting HER‐2/neu Amplification in Breast Cancer

  2005cites this paper
• Single-agent trastuzumab versus trastuzumab plus cytotoxic chemotherapy in metastatic breast cancer: a single-institution experience

  2005cites this paper
• SRL172 (killed Mycobacterium vaccae) may augment the efficacy of trastuzumab in metastatic breast cancer patients.

  2005cites this paper
• Trastuzumab plus chemotherapy: convincing survival benefit or not?

  2005cites this paper
• Real-time RT-PCR: a complementary method to detect HER-2 status in breast carcinoma.

  2005cites this paper
• Extramammary Paget's disease: analysis of growth signal pathway from the human epidermal growth factor receptor 2 protein.

  2005cites this paper
• Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer.

  2005cites this paper
• Therapy Regimens Used in Adjuvant and Neoadjuvant Treatment of the Discussed Tumor Types

  2005cites this paper
• Pharmacogenetics and the future of medicine

  2005cites this paper
• Oncogenes as Novel Targets for Cancer Therapy (Part I)

  2005cites this paper
• Oncogenes as Novel Targets for Cancer Therapy (Part IV)

  2005cites this paper
• Monoclonal Antibody Strategies for Targeting HER2

  2005cites this paper
• Pharmacogenetics in drug development

  2005cites this paper
• Predominance of high-grade pathway in breast cancer development of Middle East women

  2005cites this paper
• Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors

  2004cites this paper
• New targeted treatments in lung cancer--overview of clinical trials.

  2004cites this paper
• Pharmacogenetics and drug development: the path to safer and more effective drugs

  2004cites this paper